The present disclosure relates to microbial stem cell technology that enables a growing microbial culture to stably maintain two or more distinct cell types in a ratio that can be genetically programmed and/or dynamically controlled during cultivation. It is contemplated that embodiments described herein can be utilized to increase product yield in microbial fermentations and advanced engineering of biomaterials using genetically engineered microbial cells, among others.

Provided are compositions that include a metal-organic framework (MOF) including a framework defining an internal volume, an enzyme disposed within the internal volume, and a surfactant. Also provided are methods of making the compositions and their use.

Provided are compositions that include a metal-organic framework (MOF) including a framework defining an internal volume, an enzyme disposed within the internal volume, and a surfactant. Also provided are methods of making the compositions and their use.

Provided are a modified-type neuraminidase, a gene encoding the modified-type neuraminidase, a combination of the modified-type neuraminidase and cathepsin A, a combination of the gene encoding the modified-type neuraminidase and a gene encoding cathepsin A, a vector including said genes, and a pharmaceutical composition containing same. The pharmaceutical composition can be used for the therapy of lysosomal storage disease.

Recombinant MlrA and MlrB proteins having enzymatic activity against microcystin (MC) degrade and reduce the toxicity of MC. Compositions of the proteins can be used in the remediation of MC toxin generated from harmful cyanobacterial and algal blooms. Recombinant proteins, nucleic acids, host cells, and methods of producing the MlrA and MlrB are disclosed.

Recombinant MlrA and MlrB proteins having enzymatic activity against microcystin (MC) degrade and reduce the toxicity of MC. Compositions of the proteins can be used in the remediation of MC toxin generated from harmful cyanobacterial and algal blooms. Recombinant proteins, nucleic acids, host cells, and methods of producing the MlrA and MlrB are disclosed.

A connecting polypeptide has SEQ ID NO:73. A proinsulin polypeptide includes a mature insulin A-chain, a mature insulin B-chain, and a connecting peptide comprising SEQ ID NO: 73 linking the mature A-chain and the mature B-chain, wherein the connecting peptide is not a native human proinsulin C-peptide. The proinsulin polypeptides according to the invention can be made in high titers and in high purity.

The invention relates to antibody conjugates (e.g., a bispecific antibody), drug and nanoparticle compositions and methods and compositions for generating them. This invention further relates to methods of using these compositions for imaging, diagnosing or treating a disease.

The invention relates to antibody conjugates (e.g., a bispecific antibody), drug and nanoparticle compositions and methods and compositions for generating them. This invention further relates to methods of using these compositions for imaging, diagnosing or treating a disease.

The invention relates to the uses of a new characterized TET protein showed restricted to N-terminus glycine residues exopeptidase. The invention also relates to a method comprising said use of said new characterized TET protein as a N-terminus glycine residues specific exopeptidase. The invention further relates to a support wherein it is immobilized on said new characterized TET protein as a N-terminus glycine residues specific exopeptidase.